T o respond to diverse microbial infections, T cells differentiate into functionally distinct subsets that secrete unique combinations of cytokines (1) . Recently, a novel subset of T helper (Th) cells was identified-called Th 17 cells-that produce IL-17A, IL-17F, and IL-22 (2) . Th 17 cells protect the host against extracellular pathogens encountered at mucosal surfaces, but they also play a detrimental role in experimental models of multiple sclerosis, as well as in human inflammatory bowel disease and psoriasis (2) . In mice, cytokines TGF-␤ and IL-6 initiate the differentiation of T cells into the Th 17 lineage by inducing expression of a transcription factor called retinoic acid receptor-related orphan nuclear receptor (ROR)-␥t and of the IL-23 receptor (3) (4) (5) (6) . IL-21 and IL-23 further support the differentiation of Th 17 cells, permitting IL-22 expression (6) (7) (8) (9) (10) . In addition to providing autocrine support to the cells that produce them, some lineage-specific cytokines can impede the development of other Th lineages. For example, IL-21 secretion by Th 17 cells inhibits Th 1 cytokines (11) , whereas the reciprocal regulation of Th 1 and Th 2 responses is mediated by IL-4 and IFN-␥ (12), both of which antagonize Th 17 differentiation (13, 14) . Upon pathogen encounter, innate immune cells critically influence Th differentiation. For example, triggering of Toll-like receptors (TLRs) on dendritic cells (DCs) drives IL-12 production, which favors Th 1 differentiation. Similarly, upon engagement of their receptors dectin-1 or nucleotide oligomerization domain 2 (Nod2), DCs produce IL-6 and IL-23, which orientate T cells to the Th 17 lineage (15-17) . Other cells of the innate immune system that influence Th differentiation include invariant natural killer T cells (iNKT), a CD1d-restricted T-cell population that expresses an invariant T-cell receptor ␣-chain by using a V␣14-J␣18 rearrangement in mice and a V␣24-J␣18 rearrangement in humans. Like conventional T cells, iNKT cells comprise distinct functional subsets. Notably, NK1.1 pos iNKT cells produce IL-4 and IFN-␥, whereas NK1.1 neg iNKT cells produce IL-17 and IL-21 (18) (19) (20) (21) . The iNKT cell response is elicited by the presentation of pathogen-derived or endogenous glycolipid antigens by CD1d-expressing antigen-presenting cells (APCs) (22) . iNKT cells can support and sustain Th 1 responses by activating NK cells, which secrete IFN-␥, thus facilitating DC maturation and IL-12 production (22) . Under different inflammatory conditions, iNKT cell activation favors Th 2 differentiation by producing IL-4, thereby conferring clinical benefit in animal models of organ-specific autoimmune diseases (23) (24) (25) (26) (27) .
The ability of iNKT cells to regulate the differentiation of conventional Th 1 and Th 2 cells raises the question of whether they might also influence the Th 17 lineage. On one hand, the NK1.1 neg iNKT cell subset that produces IL-17 and IL-21 might support and sustain Th 17 responses (18-21); on the other hand, the clinical benefit provided by the activation or enrichment of iNKT cells in Th 17 -driven models of organ-specific autoimmune diseases suggests that iNKT cells might control pathogenic Th 17 responses (23-26, 28, 29) . This study investigated the influence of iNKT cells on the Th 17 response. We found that activation of iNKT cells in vivo impedes commitment of naïve CD4 ϩ T cells to the Th 17 lineage. Moreover, when comparing the Th 17 compartment between wild-type and iNKT-cell-deficient mice, we found that antigen (Ag)-experienced CD4 ϩ T cells produce more IL-17 when they are isolated from iNKT-cell-deficient mice (J␣18 Ϫ/Ϫ ). This invigorated Th 17 response in the J␣18 (4, 6, 30) . CD4 ϩ T cells from the iNKT-cell-deficient CD1d Ϫ/Ϫ mice produced up to 3-fold more IL-17 than CD4 ϩ T cells from wild-type mice (Fig. 1A) , suggesting that a CD1d-dependent T-cell population controls the Th 17 lineage. By contrast, the production of IL-4 was significantly reduced in CD4 ϩ T-cell cultures from CD1d Ϫ/Ϫ mice, indicative of the absence of iNKT cells, which produce large amounts of IL-4 in response to TCR stimulation (31) . To unequivocally assess the implication of CD1d-restricted iNKT cells we determined the cytokine production of stimulated CD4 ϩ T cells from J␣18 Ϫ/Ϫ mice that selectively lack iNKT cells. Similar to the phenotype observed with CD1d Ϫ/Ϫ mice, CD4 ϩ T cells from J␣18 Ϫ/Ϫ mice produced more IL-17 as compared with CD4 ϩ T cells from wild-type mice (Fig. 1B) , confirming that iNKT cells limit IL-17 production in vitro. Stimulated CD4 ϩ T cells from J␣18 Ϫ/Ϫ mice also produced less IL-4 than their wild-type counterparts (Fig. 1B) compatible with the absence of iNKT cells. A less pronounced reduction in IFN-␥ secretion was equally observed. To assess if the impact of iNKT cells on the Th 17 lineage extends to other mouse strains we compared the cytokine profile of stimulated CD4 ϩ T cells from wild-type and J␣18 Ϫ/Ϫ NOD mice, and observed a comparable inhibition of IL-17 secretion in the presence of iNKT cells (NOD: 864 Ϯ 110 pg/ml vs. J␣18 Ϫ/Ϫ : 2707 Ϯ 379 pg/ml; P ϭ 0.03). Interestingly, the CD4 ϩ T-cell cultures from NOD mice produced more IL-17 than C57BL/6-derived cultures, potentially reflecting the autoimmune process developing in NOD mice.
Activating iNKT Cells in Vivo Inhibits Autoantigen-Specific Th1 and Th17
Responses. To investigate the influence of iNKT cells on the Th 17 lineage in vivo, we used the mouse model of experimental autoimmune encephalomyelitis (EAE), in which immunization with a peptide fragment of myelin oligodendrocyte glycoprotein (MOG) induces myelin-specific Th 1 and Th 17 cells that synergistically contribute to the demyelinating lesions in the CNS (32, 33) . In this model, activation of iNKT cells ameliorates the disease by reducing the intensity of the pathogenic T-cell response (24) (25) (26) . To study the differentiation of autoreactive T cells at the single-cell level, we introduced a traceable population of naïve MOG -specific CD4 ϩ T cells into the mice before inducing EAE ( Fig. 2A) . These CD62L ϩ CD25 Ϫ autoreactive CD4 ϩ T cells were purified from CD45.1 congenic, 2D2 transgenic mice expressing an I-A b -restricted TCR (V␣3.2-V␤11) specific for MOG on CD4 ϩ T cells. These transferred MOG-specific T cells underwent an expansion of up to 3,700-fold, 9 days after immunization with MOG (Fig. S1 ). Analysis of the intracellular cytokine profile of the congenic (CD45.1 ϩ ) MOG-specific T cells by FACS enabled us to quantify IFN-␥-producing Th 1 and IL-17-producing Th 17 cells (Fig. S1 A) . Both the Th 1 and Th 17 responses peaked 9 days after immunization in the spleen (Fig. S1B ) and draining lymph nodes (LNs; data not shown), but the number of Th 17 cells was significantly inferior to that of Th 1 cells. These mice developed moderate clinical signs of EAE, on average, 17 days after immunization (Fig. 2) .
To validate the regulatory capacity of iNKT cells in this model, we treated immunized mice with 2 injections of ␣-GalCer (Fig. 2 A) , an exogenous glycolipid that closely resembles the microbial glycosphingolipids that are agonists of iNKT cells (34) . These injections significantly reduced the severity of EAE when compared with the vehicle-injected control mice (Fig. 2B) . In vitro recall responses to MOG revealed that ␣-GalCer injections inhibited the antigen-specific secretion of IL-17 ( Fig.  3A) , IFN-␥, and TNF-␣ (data not shown) by splenocytes. This was not due to loss of MOG-specific CD45.1 ϩ CD4 ϩ T cells, which were only slightly reduced after ␣-GalCer treatment ( ϩ T cells (data not shown). Interestingly, although the activation of iNKT cells also reduced the frequency (Fig. 3E ) and slightly reduced the absolute numbers (vehicle: 34 Ϯ 12 ϫ 10 3 vs. ␣-GalCer: 8 Ϯ 2 ϫ 10 3 ; P ϭ 0.1) of Th 1 cells, its impact on the Th 1 response appeared more modest than on the Th 17 response. This inhibition of the MOG-specific Th 17 and Th 1 responses is attributable to iNKT cells because ␣-GalCer treatment of J␣18 Ϫ/Ϫ mice had no significant influence on the expansion and differentiation of autoreactive T cells (Fig. 3 B, D , and E). Similar results were obtained with cells from the draining LNs, where ␣-GalCer treatment influenced expansion only modestly (Fig. 4A ), but blunted IFN-␥ and IL-17 production by MOG-specific CD4 ϩ T cells in an iNKT-cell-dependent manner (Fig. 3 F and G and Fig.  S2 ). Taken together, our data show that activation of iNKT cells Fig. 3 . Activation of iNKT cells by ␣-GalCer blocks the commitment of naïve MOG-specific T cells to the Th 1 and Th17 lineages. By using the 2D2 transfer model described in Fig. 2 , we assessed MOG-specific T-cell differentiation in immunized C57BL/6 (WT) and J␣18 Ϫ/Ϫ recipient mice treated with ␣-GalCer or vehicle. (A) Nine days after immunization, we assessed the in vitro recall response by splenocytes from ␣-GalCer-treated recipients (white bars; WT, n ϭ 4; J␣18 Ϫ/Ϫ , n ϭ 4) or vehicle-treated recipients (black bars; WT, n ϭ 4; J␣18 Ϫ/Ϫ , n ϭ 4). IL-17 release was measured from unstimulated (NS), MOG 35-55-stimulated (MOG; 100 g/ml), and anti-CD3 mAbstimulated (CD3) cultures after 72 h. (B) The number of CD45.1 ϩ TCRV␣3.2 ϩ CD4 ϩ T cells was established in mice treated with ␣-GalCer (white bars; WT, n ϭ 11; J␣18 Ϫ/Ϫ , n ϭ 4) or vehicle (black bars; WT, n ϭ 11; J␣18 Ϫ/Ϫ , n ϭ 4). ␣-GalCer slightly reduced the proportion of 2D2 CD45.1 ϩ TCRV␣3.2 ϩ CD4 ϩ T cells in the spleens of WT but not J␣18 Ϫ/Ϫ mice. (C-G) The MOG-specific Th 17 and Th 1 differentiation was analyzed by establishing the intracellular IL-17 and IFN-␥ production of CD45.1 ϩ TCRV␣3.2 ϩ CD4 ϩ T cells from WT and J␣18 Ϫ/Ϫ recipient mice treated with ␣-GalCer or vehicle. Th17 differentiation is indicated by the frequency of IL-17-producing 2D2 T cells in the spleen (C and D) and draining LNs (F). Th 1 differentiation is indicated by the frequency of IFN-␥-producing 2D2 T cells in the spleen (C and E) and draining LNs (G). Intracellular cytokine analyses were also performed after antigen-specific restimulation with MOG and revealed a similar inhibition of Th 1 and Th17 responses by ␣-GalCer treatment, although the number of cytokine-positive cells was generally lower. Cytokine secretion in (A) presents 1 representative experiment of 3 performed. Intracellular cytokine analyses in (B-G) present 3 independent experiments for the WT mice and 1 experiment for J␣18 Ϫ/Ϫ mice. ϩ T cells was observed among congenic 2D2 T cells and in the endogenous CD4 ϩ T-cell pool (Fig. 4B) . Evidence of immune deviation was obtained, as the proportion of IL-4-producing congenic 2D2 CD4 ϩ T cells (and endogenous Th 2 cells; data not shown) augmented significantly in ␣-GalCer-treated wild-type mice when compared with the vehicle-treated mice (Fig. 4C and Fig. S2) , and their restimulation in vitro is associated with elevated levels of the Th 2 -associated cytokine IL-5 (Fig. 4D) . By contrast, ␣-GalCer treatment of J␣18 Ϫ/Ϫ mice had no effect on the frequency of Th 2 cells and their associated cytokines (Fig. 4 C and D) , indicating that the Th 2 bias seen in wild-type mice depended on iNKT cells. Interestingly, an enhanced production of IL-10 was observed in cultures from ␣-GalCer-treated mice (Fig. 4E ) irrespective of MOG restimulation. In addition, no detectable increase in the frequency of IL-10-producing MOG-specific 2D2 T cells (Fig. S2) was observed, suggesting that iNKT cells can promote IL-10 production by non-T cells.
To assess whether IL-4 and IL-10 contributed to the inhibition of Th 1 and Th 17 differentiation by the in vivo ␣-GalCer treatment, we neutralized the effects of both IL-4 and IL-10 with mAbs injected i.p. Under these cytokine-blocking conditions, the proportion of Th 1 2D2 cells tripled and the regulatory effect of iNKT cell activation by ␣-GalCer on Th 1 cells was fully blocked (Fig. 4F and Fig. S3A) . Concomitantly, the proportion of Th 17 cells increased. Nevertheless, ␣-GalCer treatment still significantly limited the Th 17 response (Fig. 4G and Fig. S3A ). Given the capacity of iNKT cells to produce copious amounts of IFN-␥ (22), the increase in IFN-␥-producing Th 1 cells after IL-4 and IL-10R neutralization, and the capacity of IFN-␥ to antagonize Th 17 differentiation (13, 14), we asked whether IFN-␥ could be an additional factor involved in the regulation of Th 17 commitment by iNKT cells. Neutralizing IFN-␥ in vivo doubled the proportion of Th 17 2D2 CD4 ϩ T cells in both PBS and ␣-GalCer-treated mice (Fig. S3B) . Nevertheless, ␣-GalCer remained efficient in reducing the frequency of Th 17 cells, indicating that IFN-␥ is necessary but not sufficient for the iNKTcell-mediated regulation of the Th 17 response (Fig. S3A) . Importantly, neutralizing IL-4, IL-10, and IFN-␥ simultaneously tripled the proportion of Th 17 cells and fully abrogated the capacity of ␣-GalCer to inhibit Th 17 commitment (Fig. 4H and  Fig. S3A ). Blocking IL-4 ϩ IL-10R and/or IFN-␥ also prevented the EAE-protective effect of ␣-GalCer, rendering these mice susceptible to severe disease (Table S1 ). We conclude that iNKT-cell-induced IL-4 and IL-10 production mediates the inhibition of the Th 1 response, whereas the regulation of Th 17 commitment by iNKT cells requires IL-4, IL-10, and IFN-␥.
INKT Cells Regulate the Th17 Compartment at Steady State.
Having established that iNKT cells control Th 17 differentiation, we aimed to assess whether this cellular mechanism is of importance in controlling the Th 17 compartment under steady-state conditions in vivo. To this end, we compared IL-17 production by Ag-experienced CD4 ϩ T cells from wild-type and J␣18
Ϫ/Ϫ mice in vitro. Splenic CD62L Ϫ CD4 ϩ T cells were purified by FACS sorting. In addition, using the CD1d-␣GalCer tetramer we eliminated iNKT cells to exclude their potential in vitro effects. Polyclonal activation in vitro revealed a 2-fold enhancement of IL-17 production when the Ag-experienced T cells were isolated from J␣18 Ϫ/Ϫ mice when compared with those isolated from wild-type mice (Fig. 5A) . No influence on the IFN-␥ response was observed (cells from wild-type mice produced 3,150 pg/ml IFN-␥, those from J␣18 Ϫ/Ϫ mice produced 3,155 pg/ml IFN-␥). IL-17 production by Ag-experienced CD4 ϩ T cells was not affected by neutralization of IL-4 and IFN-␥ in vitro (Fig. 5B) , consistent with the reported resistance of committed Th 17 cells to IL-4-and IFN-␥-mediated regulation (13, 14) . These findings suggest that iNKT cells control the Th 17 compartment in vivo at steady state as they limit the IL-17-producing capacity of Agexperienced CD4 ϩ T cells.
To investigate this novel function of iNKT cells in vivo, we reconstituted iNKT-deficient nonirradiated J␣18 Ϫ/Ϫ mice with iNKT cells by adoptive transfer of 10 6 CD1d:␣-GalCer tetramerpositive TCR-␣␤ thymocytes from wild-type mice. We assessed the impact of this iNKT cell reconstitution on the Th 17 population after 21 days, a period that is probably insufficient for the Th17 compartment to be replenished by de novo activated naïve T cells at steady state. Thus, the data likely reflect the impact of the introduced iNKT cells on preexisting Ag-experienced cells. CD1d:␣-GalCer tetramer staining revealed efficient grafting of wild-type iNKT cells in J␣18 Ϫ/Ϫ mice as indicated by the 4% frequency of CD1d:␣-GalCer tetramer-positive cells among liver mononuclear cells (Fig. 5C) . Strikingly, this grafting of wild-type iNKT cells fully reversed the enhanced IL-17 production by CD4 ϩ T cells from J␣18 Ϫ/Ϫ mice (Fig. 5D ), demonstrating that iNKT cells control the Th 17 compartment at steady state. This effect was specific for the Th 17 lineage because we observed no alteration in IFN-␥ production by the Th 1 compartment (Fig.  5E) . No reciprocal induction of Foxp3 ϩ regulatory T cells was observed after iNKT-cell reconstitution (data not shown). To address whether the transferred iNKT cells impacted the frequency of Th 17 cells in vivo we enumerated the proportion of IL-17-producing CD4 ϩ T cells using intracellular cytokine staining. The reconstitution of iNKT cells reduced the frequency of Th 17 cells almost to the level observed in unmanipulated WT mice (Fig. 5F ). These splenic CD4 ϩ T-cell cultures from reconstituted mice express on average 0.05% of iNKT cells (Fig. 5C ), making an in vitro effect by iNKT cells unlikely. As such, our findings reveal a previously undescribed function for iNKT cells in regulating the size of the Th 17 pool in vivo at steady state.
Conclusions. Th 17 cells contribute to the host defense against extracellular pathogens, but excessive Th 17 responses or those targeting self-antigens can provoke severe tissue injury (2, 36) . Mechanisms controlling the Th 17 subset might therefore be important to preserve the integrity of tissues. Our study reveals the importance of iNKT cells in regulating Th 17 Th 17 responses contribute to demyelinating lesions in the CNS (32, 33) . This observation might also be of relevance for microbial infections where iNKT cells are activated by either pathogenderived or endogenous glycolipid antigens presented in the hydrophobic groove of CD1d (37) (38) (39) . It is conceivable that the activation of iNKT cells during infections might similarly influence T-cell differentiation and prevent the induction of an excessive Th 17 response, thereby limiting secondary tissue damage.
Importantly, we show that iNKT cells also impact on the Th 17 pool in vivo in unmanipulated mice. We reveal that iNKT cells restrain IL-17 production by CD4 ϩ T cells in both C57BL/6 and autoimmune-prone NOD mice. Strikingly, the enhanced IL-17 production observed in iNKT-cell-deficient mice was fully reversed by the transfer of thymic iNKT cells. This was associated with the capacity of the transferred iNKT cells to reduce the frequency of Th 17 cells in vivo, restoring a Th 17 frequency similar to that observed in WT mice. Because no effect on IFN-␥ production by antigen-experienced Th 1 cells was observed, it is assumed that iNKT cells specifically control the persistence of Ag-experienced Th 17 cells. Under steady-state conditions, iNKT cells are activated and functionally engage dendritic cells and B cells (40, 41) , which is thought to be of importance to prepare the host for future pathogen encounter. Our findings suggest that, in addition, iNKT cells impact on Ag-experienced CD4
ϩ T cells at steady state, implying a role for iNKT cells in shaping the T-cell response before pathogen exposure. Given the role of the Th 17 cell subset in inflammatory tissue damage, its confinement by iNKT cells might provide a barrier that limits predisposition to inflammatory diseases and supports iNKT cells as a therapeutic target in Th 17 mediated diseases (42) .
Materials and Methods
Mice, EAE Induction, and in Vivo Treatments. C57BL/6 mice (Charles River Laboratories), CD1d Ϫ/Ϫ mice (43), J␣18 Ϫ/Ϫ mice (44), 2D2 MOG-TCR mice (45) , and NOD mice were housed under specific pathogen-free conditions. All experimental protocols were approved by the local ethics committee and are in compliance with European Union guidelines. EAE was induced by s.c. immunization with 50 g of MOG35-55 peptide (MEVGWYRSPFSRVVH-LYRNGK; Mimotopes) emulsified in CFA (Difco) and 2 i.v. injections of pertussis toxin (day 0, 200 ng; day 2, 400 ng; List Biological Laboratories). Disease severity was monitored daily (28) . Where indicated, mice were treated with two 4-g doses of ␣-GalCer (Kirin Brewery) on day 0 (emulsified in the MOG CFA mixture) and day 4 (i.p.) or with anti-IL-4 (11B11), anti-IL10R (1B1), or anti-IFN-␥ (XMG1.2) mAbs injected i.p. at a dose of 0.5 mg/mouse on days Ϫ3, Ϫ2, 0, 2, 5, and 8 for 2D2 differentiation, or days Ϫ2, Ϫ1, 0, 3, (0.5 mg/mouse) and 5, 9, 13, 17, and 21 (0.15 mg/mouse) for EAE.
T-Cell Purification and Adoptive Transfer. Splenic CD4 ϩ T cells were isolated (Ͼ94% pure) by MACS positive selection (Miltenyi Biotec). Subsequently, conventional Ag-experienced CD4 ϩ (CD1d:␣-GalCer tetramer neg CD62L Ϫ CD4 ϩ ) T cells were isolated by FACS (Ͼ97% pure). MOG-specific naïve CD62L ϩ CD25 Ϫ CD4 ϩ cells were purified from CD45.1 congenic 2D2 mice by MACS negative selection (Miltenyi Biotec) by using anti-CD8 (YTS169), anti-B220 (RA3-6B2), anti-Mac1 (CI:A3-1), and anti-CD25 (7D4) mAbs followed by positive selection with anti-CD62L-coated beads, providing Ͼ80% CD4 ϩ T cells, of which 95% expressed the transgenic 2D2 TCR. For reconstitution studies, freshly isolated thymocytes were enriched for iNKT cells by CD8 depletion (Invitrogen Life Technology); 3%Ϫ5% of recovered thymocytes were CD1d:␣-GalCer tetramer ϩ TCR␤ ϩ iNKT cells. The equivalent of 1.0 ϫ 10 6 iNKT cells was adoptively transferred i.v. into J␣18 Ϫ/Ϫ mice. LSRII flow cytometer (Becton Dickinson) using the BD FACS-Diva software. Cell sorting was performed using a FACSAria Flow Cytometer (Becton Dickinson).
In Vitro Cytokine Production. 2.0 ϫ 10 5 CD4 ϩ T cells or 0.5 ϫ 10 5 Ag-experienced CD4 ϩ T cells were cultured with plate-bound anti-CD3 (1 g/ml) and anti-CD28 (10 g/ml) mAbs (BD Biosciences) and IL-23 (10 ng/ml; R&D Systems). When indicated, anti-IFN-␥ (10 g/ml) and anti-IL-4 (10 g/ml) mAbs (BD Biosciences) were added. For in vitro recall responses, single-cell suspensions of LN cells (0.5 ϫ 10 6 /well) or splenocytes (1 ϫ 10 6 /well) were cultured with the indicated stimuli. Supernatants were analyzed for IFN-␥, IL-17A, or IL-4 by Duoset ELISA (R&D Systems) or tested for 10 different cytokines (IFN-␥, TNF-␣, CXCL10, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, and IL-17A) by using LINCOplex Multiplex immunoassays and Luminex instrumentation (Millipore).
Statistical Analyses. Data are presented as means of n individual mice per group Ϯ SEM, unless otherwise stated. The Mann-Whitney U test was used, except for cytokine production, which was analyzed using the unpaired Student t test. Kinetics of EAE development was analyzed using the log rank test; EAE incidence and mortality using a 2 test; and severity using the Mann-Whitney U test. *, P Ͻ 0.05, **, P Ͻ 0.01, ***, P Ͻ 0.001.
